Aquestive Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Aquestive Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue57.5650.5847.6850.8345.8552.6167.43
Cost of Revenue17.8720.8319.3914.99-12.96-20.3620.99
Gross Profit39.6929.7528.2935.8445.8532.2546.44
Operating Expenses
Research & Development20.2813.1017.4817.0519.8920.5723.11
Selling, General & Administrative50.1831.7552.8853.4855.8964.3472.27
Operating Expenses70.4644.8570.3685.5188.7484.9295.38
Operating Income-30.77-15.10-42.07-34.68-42.89-52.67-48.94
Other Income/Expense
Interest Income3.4416.320.100.420.130.000.55
Interest Expense16.827.4612.4422.46-13.020.007.71
Other Income/Expense-13.38-1.380.0013.820.454.90-5.28
Income
Income Before Tax-44.15-7.63-54.41-70.54-55.78-66.25-61.38
Income Tax Expense-0.010.250.000.000.000.000.00
Net Income-44.14-7.87-54.41-70.54-55.78-66.25-61.38
Net Income - Continuous Operations-44.14-7.87-54.41-70.540.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-26.621.18-39.58-45.11-39.32-52.09-50.43
EBIT-27.33-0.16-41.97-48.08-42.76-56.93-53.67
Depreciation & Amortization0.721.352.392.913.39-2.850.00
Earnings Per Share
Basic EPS-1.00--1.00-2.00-2.00--3.00
Diluted EPS-1.00--1.00-2.00-2.00-3.00-3.00
Basic Shares Outstanding86.7361.2648.7338.0833.6525.3620.73
Diluted Shares Outstanding86.7361.2648.7338.0833.6025.3820.73